Director/PDMR Shareholding

Report this content

24 February 2023 11:00 GMT

Transaction by Person Discharging Managerial Responsibilities

AstraZeneca PLC (the Company) announces that, on 22 February 2023, it was notified by Aradhana Sarin, Executive Director and Chief Financial Officer, that, on 17 February 2023, Dr Sarin ceased to be beneficially interested in 200 American Depositary Shares (ADSs) of the Company, following the gift of those shares to charity for nil consideration. Each ADS represents one half of an ordinary share of $0.25 each in the Company.

Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018.

1 Details of the person discharging managerial responsibilities / person closely associated
a) Name Aradhana Sarin
 
2 Reason for the notification
 
a) Position/status Chief Financial Officer
 
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name AstraZeneca PLC
 
b) LEI PY6ZZQWO2IZFZC3IOL08
 
4i Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument

Identification code
AstraZeneca PLC American Depositary Shares


CUSIP: 046353108

 
b) Nature of the transaction Gift of shares to charity for nil consideration
 
c) Price(s) and volume(s)
Price(s) Volume(s)
0 200
d) Aggregated information

- Aggregated volume
- Price

 
Not applicable - single transaction
e) Date of the transaction 17 February 2023
 
f) Place of the transaction Outside a trading venue
 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Adrian Kemp
Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Subscribe

Documents & Links